Stocks and Investing Stocks and Investing
Tue, August 9, 2022

Christopher Raymond Maintained (BMRN) at Buy with Increased Target to $128 on, Aug 9th, 2022


Published on 2024-10-27 22:32:21 - WOPRAI, Christopher Raymond
  Print publication without navigation


Christopher Raymond of Piper Sandler, Maintained "BioMarin Pharmaceutical Inc." (BMRN) at Buy with Increased Target from $125 to $128 on, Aug 9th, 2022.

Christopher has made no other calls on BMRN in the last 4 months.



There are 6 other peers that have a rating on BMRN. Out of the 6 peers that are also analyzing BMRN, 1 agrees with Christopher's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Andreas Argyrides of "Wedbush" Initiated at Hold and Held Target at $70 on, Monday, June 13th, 2022


These are the ratings of the 5 analyists that currently disagree with Christopher


  • Gena Wang of "Barclays" Maintained at Buy with Increased Target to $125 on, Thursday, August 4th, 2022
  • Joseph Schwartz of "SVB Leerink" Maintained at Buy with Increased Target to $122 on, Thursday, August 4th, 2022
  • Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $117 on, Thursday, August 4th, 2022
  • Olivia Brayer of "Cantor Fitzgerald" Initiated at Buy and Held Target at $110 on, Wednesday, July 13th, 2022
  • Tiago Fauth of "Credit Suisse" Maintained at Buy with Increased Target to $106 on, Monday, June 6th, 2022
Contributing Sources